Chronic Spontaneous Urticaria Market Expansion 2024-2033: Growth Drivers and Dynamics

Market Size –
The chronic spontaneous urticaria market size has grown strongly in recent years. It will grow from $1.90 billion in 2023 to $2.06 billion in 2024 at a compound annual growth rate (CAGR) of 8.3%. The growth in the historic period can be attributed to improved diagnostic tools, growing awareness among healthcare, patient advocacy and support groups, ongoing studies and clinical trials exploring new therapies, and growing healthcare expenditure.

The chronic spontaneous urticaria market size is expected to see strong growth in the next few years. It will grow to $2.84 billion in 2028 at a compound annual growth rate (CAGR) of 8.4%. The growth in the forecast period can be attributed to an increase in the number of diagnosed CSU cases, a growing patient pool, healthcare infrastructure development, favorable regulatory environment facilitating, patient-centric care models, and economic growth in emerging markets. Major trends in the forecast period include technology innovations, biological therapy advancements, personalized medicine, telemedicine and digital health, advanced diagnostic tools, AI and machine learning, and surging drug approvals and launches.

Order your report now for swift delivery @
https://www.thebusinessresearchcompany.com/report/chronic-spontaneous-urticaria-global-market-report

Scope Of Chronic Spontaneous Urticaria Market
The Business Research Company’s reports encompass a wide range of information, including:

1. Market Size (Historic and Forecast): Analysis of the market’s historical performance and projections for future growth.

2. Drivers: Examination of the key factors propelling market growth.

3. Trends: Identification of emerging trends and patterns shaping the market landscape.

4. Key Segments: Breakdown of the market into its primary segments and their respective performance.

5. Focus Regions and Geographies: Insight into the most critical regions and geographical areas influencing the market.

6. Macro Economic Factors: Assessment of broader economic elements impacting the market.

Chronic Spontaneous Urticaria Market Overview

Market Drivers –
Increasing alcohol consumption is expected to propel the growth of the chronic spontaneous urticaria market going forward. The rising consumption of alcohol can be attributed to various factors, such as social norms, stress, advertising, affordability, and availability. Alcohol consumption can potentially exacerbate symptoms of chronic spontaneous urticaria in some individuals, leading to increased hives and swelling. For instance, in February 2024, according to rehabs.UK, a UK-based provider of addiction recovery support and advice services, 55% of men reported weekly alcohol consumption, while 41% of women. Additionally, 8% of men reported drinking alcohol almost daily, compared to 5% of women. Over the years from 2021 to 2022, there were 342,795 hospital admissions solely attributable to alcohol, translating to a rate of 626 admissions per 100,000 people. Therefore, increasing alcohol consumption is driving the growth of the chronic spontaneous urticaria market.

Market Trends –
Major companies operating in the chronic spontaneous urticaria market are developing advanced next-generation monoclonal anti-immunoglobulin E (IgE) antibodies to enhance treatment efficacy and reduce dosing frequency. Next-generation monoclonal anti-immunoglobulin E (IgE) antibodies refer to newer versions designed to improve efficacy and dosing intervals in treating conditions such as chronic spontaneous urticaria. For instance, in January 2021, Novartis AG, a Switzerland-based pharmaceutical company, received US Food and Drug Administration approval for the ligelizumab (QGE031) Breakthrough Therapy designation for the treatment of chronic spontaneous urticaria (CSU) in patients who have an inadequate response to H1-antihistamine treatment. Ligelizumab is the first treatment to receive this designation at CSU.

The chronic spontaneous urticaria market covered in this report is segmented –

1) By Treatment: Medication, Phototherapy, Other Treatments
2) By Route Of Administration: Oral, Topical, Parenteral, Other Routes Of Administration
3) By Diagnosis: Physical Examination, Blood Test, Allergy Test, Other Diagnosis
4) By End-Users: Hospitals, Specialty Clinics, Homecare, Other End-Users

Get an inside scoop of the chronic spontaneous urticaria market, Request now for Sample Report @
https://www.thebusinessresearchcompany.com/sample.aspx?id=16651&type=smp

Regional Insights –
North America was the largest region in the chronic spontaneous urticaria market in 2023. The regions covered in the chronic spontaneous urticaria market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Key Companies –

Major companies operating in the chronic spontaneous urticaria market are F. Hoffmann-La Roche Ltd., Merck & Co. Inc., AbbVie Inc., Bayer AG, Sanofi SA, AstraZeneca plc, Novartis AG, GlaxoSmithKline plc, Eli Lilly and Company, Amgen Inc., Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., Aurobindo Pharma Limited, Cipla Limited, Genentech Inc., Dr. Reddy’s Laboratories Ltd., Hikma Pharmaceuticals plc, Celltrion Inc., Allakos Inc., United BioPharma Inc.

Table of Contents
1. Executive Summary
2. Chronic Spontaneous Urticaria Market Characteristics
3. Chronic Spontaneous Urticaria Market Trends And Strategies
4. Chronic Spontaneous Urticaria Market – Macro Economic Scenario
5. Global Chronic Spontaneous Urticaria Market Size and Growth
.
.
.
31. Chronic Spontaneous Urticaria Market Other Major And Innovative Companies
32. Global Chronic Spontaneous Urticaria Market Competitive Benchmarking
33. Global Chronic Spontaneous Urticaria Market Competitive Dashboard
34. Key Mergers And Acquisitions In The Chronic Spontaneous Urticaria Market
35. Chronic Spontaneous Urticaria Market Future Outlook and Potential Analysis
36.Appendix

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293

Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model